Skip to content
Evolving Standards in Familial Hypercholesterolemia: Innovations in Diagnosis and Therapeutic Strategies
Thank You for Joining Us!
Please complete the following evaluation to claim your credit for the podcast
*
1.
Please Complete the following
(Required.)
First Name
*
Last Name
*
Degree
*
Email Address
*
Pharmacist Only- NABP ID
Pharmacist Only- Date of Birth (MM/DD)
2.
Are you an NLA member?
Yes
No
Not sure
3.
What is your area of specialization?
Cardiology
Family Medicine
General Practice
Internal Medicine
Endocrinology
Other
4.
How long have you been in practice?
<1 year
1-5 years
6-10 years
11-20 years
>20 years
I do not directly provide care
5.
How many patients with dyslipidemia do you currently see each week?
<5
5-15
16-25
26-35
36-45
>45
I do not directly provide care.
*
6.
Please mark your response to the following questions:
After participating in this activity, I am able to:
(Required.)
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
Describe the evolving paradigms in the diagnosis and care of FH, including the rates of heterozygous FH (HeFH) and homozygous FH (HoFH), and the low rates of screening in children.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
Discuss the expanding role of genetic testing in FH, including its use for risk stratification and its potential to predict a patient's response to therapies such as PCSK9 inhibitors.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
Evaluate and apply various lipid-lowering strategies, including combination approaches, to optimize treatment for FH patients.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
*
7.
Please mark your response to the following questions:
Rate your level of agreement with the statement(s) below:
(Required.)
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
My opportunity for learning assessment was appropriate to the activity.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
The content presented enhanced my current knowledge base.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
The content presented was scientifically rigorous and evidence-based.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
The scope, depth, and level of content were appropriate.
1- Strongly Disagree
2- Disagree
3- Neutral
4- Agree
5- Strongly Agree
8.
An 18 year old woman comes to see you for large lumps on her Achilles tendons that have been noticeable since she was 8 years old. Her lipid panel is as follows: total cholesterol 600mg/dL, triglycerides 100mg/dL, HDL-cholesterol 45mg/dL, LDL-cholesterol 535 mg/dL. All other laboratory tests are normal. Which of the following is the most likely diagnosis?
Heterozygous familial hypercholesterolemia
Homozygous familial hyperchosterolemia
Dysbetalipoproteinemia
Lipoprotein lipase deficiency
Cerebrotendinous xanthomatosis
9.
Which of the following nonstatin LDL-C lowering therapies can lower LDL-C by 50% or more?
Alirocumab
Bempedoic acid
Ezetimibe
Bempedoic acid with ezetimibe
10.
Which of the following clinical strategies is a team-based approach to improving LDL-C lowering in patients with FH?
Providing counseling by a dietitian in every FH patient prior to starting pharmacologic therapy
Deploying clinical pharmacists to titrate therapy to recommended LDL-C goals
Having a geneticist consult on all patients with FH to recommend appropriate initial pharmacologic therapy
Add an electronic health record alert recommending advanced lipid testing for all patients with LDL-C values 190mg/dL or higher
*
11.
Was this activity fair and balanced?
(Required.)
Yes
No
If you answered No, please explain:
*
12.
Did the activity avoid commercial bias or influence?
(Required.)
Yes
No
If you answered No, please explain:
*
13.
The faculty provided a disclosure and disclosed any off-label/investigational use of products discussed before the start of the activity.
(Required.)
Yes
No
If you answered No, please explain:
14.
As a result of participating in this activity, what will you do differently to improve the care of your patients?
*
15.
Select the one option below that most applies with this statement: Based upon my participation in this activity, I:
(Required.)
Gained new strategies, skills or information that I can apply to my area of practice.
Need more information before I can implement new strategies/skills/information into my practice behavior.
Will not change my practice, as my current practice is consistent with information presented.
Will not change my practice, as I do not agree with the information presented.
16.
If you gained new strategies, skills, and/or information that you plan to implement into your practice, what types of changes do you plan to implement?
17.
What barriers do you see to implementing these changes in your practice?
18.
Please provide any additional comments related to the activity in the space below.
*
19.
Please indicate the type of credit you are claiming
(Required.)
ACCME- Physician
ANCC- Nursing
ACPE- Pharmacy
Participation- All Other